Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05189821 · ClinicalTrials.gov registry record
RFA Treatment for Papillary Thyroid Microcarcinoma
A clinical trial of Papillary Thyroid Microcarcinoma, sponsored by Columbia University.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05189821: Recruiting study of Papillary Thyroid Microcarcinoma, sponsored by Columbia University.
NCT05189821 is a study of Papillary Thyroid Microcarcinoma that is actively recruiting participants, run by Columbia University. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05189821, a study of Papillary Thyroid Microcarcinoma, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Thyroid surgery has always been the mainstay of treatment for thyroid cancer. Thyroid surgery carries a low risk of complications that include recurrent or superior laryngeal nerve injury leading to voice changes, hypoparathyroidism, hypothyroidism with need for thyroid hormone supplementation, and unsightly scarring. Although many patients with thyroid cancer find these risks acceptable, these risks are sometimes less acceptable to patients with benign disease. In an era when the medical field is treating thyroid diseases less aggressively, there is a pressing need to identify approaches to treat indolent malignant disease less invasively. The purpose of this observational study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of Papillary Thyroid Microcarcinoma (PTMC) in patients that have already agreed to RFA procedure based on treating physician recommendation. This is a data collection study in which we ask participants to give us access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target tumor. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.
Primary Outcome
Rate of complete sonographic disappearance of primary tumor s/p RFA
Conditions Studied
Interventions
- PROCEDURE Radiofrequency Ablation
Study Locations (1)
New York
- Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2027-11 |
What NCT05189821 shows while recruiting
NCT05189821 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 1 condition, with Papillary Thyroid Microcarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Ablation is the first listed.
NCT05189821 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05189821 about?
NCT05189821 is a clinical study titled "RFA Treatment for Papillary Thyroid Microcarcinoma". Thyroid surgery has always been the mainstay of treatment for thyroid cancer. Thyroid surgery carries a low risk of complications that include recurrent or superior laryngeal nerve injury leading to voice changes, hypoparathyroidism, hypothyroidism with need for thyroid hormone supplementation, and ...
What is the current status of trial NCT05189821?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2021-11-01. Estimated completion is 2027-11.
What conditions does trial NCT05189821 study?
This clinical trial studies the following conditions: Papillary Thyroid Microcarcinoma.
What interventions are being tested in trial NCT05189821?
The interventions under investigation include: Radiofrequency Ablation (PROCEDURE).
Who is sponsoring clinical trial NCT05189821?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05189821 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillary Thyroid Microcarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI